GlassScriptPhysician profile
Myung Yoo
NPI 1518120955
$9,327.29
in general payments reported to CMS, 2019-2025
33 companies · $859 in 2025
The $859 reported for 2025 was more than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
See the full distribution for Pain Medicine (Physical Medicine & Rehabilitation)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $749 · 2020: $283 · 2021: $753 · 2022: $2,186 · 2023: $3,028 · 2024: $1,469 · 2025: $859.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,875 · Travel and Lodging: $1,481.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,875.09 |
| Travel and Lodging | $1,480.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,912.61 | 2022-2025 | Intellis Adaptivestim |
| Abbott Laboratories | $1,447.98 | 2020-2025 | Eterna, Proclaim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $925.10 | 2019-2025 | Relistor |
| Abbvie INC. | $878.90 | 2022-2025 | Botox, Ubrelvy, Qulipta |
| Ibsa Pharma INC. | $612.72 | 2020-2024 | Tirosint, Licart, Licart |
| Merz North America, INC. | $334.85 | 2019 | |
| Scilex Pharmaceuticals INC. | $334.15 | 2020-2025 | Ztlido |
| Nevro Corp. | $287.01 | 2022-2023 | Senza |
| Pfizer INC. | $239.09 | 2019-2023 | |
| Collegium Pharmaceutical, INC. | $231.80 | 2022-2025 | Xtampza, Belbuca |
| Uswm, LLC | $172.17 | 2021-2023 | Lucemyra, Zimhi |
| Ferring Pharmaceuticals INC. | $113.00 | 2024-2025 | Euflexxa |
| Kowa Pharmaceuticals America, INC. | $97.95 | 2022-2023 | Seglentis |
| Mdd US Operations, LLC | $88.40 | 2019-2021 | |
| Hikma Pharmaceuticals USA | $81.02 | 2022-2023 | Kloxxado |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Saluda Medical Americas, INC. | $76.97 | 2024 | Evoke |
| Allergan, INC. | $69.42 | 2019-2021 | |
| Azurity Pharmaceuticals, INC. | $56.48 | 2023-2025 | Horizant, Horizant |
| Bioventus LLC | $52.46 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $49.58 | 2021 | |
| Vertos Medical, INC. | $33.60 | 2024 | Mild Device Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $27.06 | 2022 | |
| Kaleo, INC. | $25.91 | 2019 | |
| Merz Pharmaceuticals, LLC | $25.52 | 2022 | |
| Masimo Corporation | $24.74 | 2023 | Patient Safetynet System |
| Pacira Therapeutics, INC. | $21.70 | 2020 | |
| Medtronic USA, INC. | $18.31 | 2019 | |
| Averitas Pharma INC. | $18.30 | 2024 | Qutenza |
| Redhill Biopharma INC. | $17.28 | 2022 | |
| Valinor Pharma, LLC | $15.54 | 2025 | Movantik |
| Fidia Pharma USA INC. | $14.49 | 2023 | Hymovis, Triluron |
| Lilly USA, LLC | $12.14 | 2020 | |
| Horizon Therapeutics Plc | $11.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Myung Yoo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.